Cemiplimab
- Generic Name
- Cemiplimab
- Brand Names
- Libtayo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1801342-60-8
- Unique Ingredient Identifier
- 6QVL057INT
- Background
Cemiplimab is a fully human monoclonal antibody that works against programmed death receptor-1 (PD-1), which is a negative regulator of T cell function. By blocking PD-1, cemiplimab works to enhance T cell-mediated antitumour responses.
...
- Indication
Cemiplimab is indicated to treat:
- Associated Conditions
- Locally Advanced Basal Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Metastatic cutaneous squamous cell carcinoma, Recurrent Cervical Cancer, Metastatic Basal cell carcinoma
- Associated Therapies
- First Line Chemotherapy
Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-01-28
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 36
- Registration Number
- NCT04243616
- Locations
- 🇺🇸
Froedtert Hospital & Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC
- Conditions
- Interventions
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2022-11-04
- Target Recruit Count
- 3
- Registration Number
- NCT04242173
- Locations
- 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2024-02-23
- Target Recruit Count
- 25
- Registration Number
- NCT04177810
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 79
- Registration Number
- NCT04154943
- Locations
- 🇩🇪
Regeneron Study Site, Tübingen, Germany
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Replimune Inc.
- Target Recruit Count
- 231
- Registration Number
- NCT04050436
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇫🇷CHU Besancon - Hopital Jean Minjoz, Besancon, France
🇩🇪Universitatsklinikum Heidelberg: National Centre for Tumour Diseases (NCT), Heidelberg, Germany
Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 40
- Registration Number
- NCT04006119
- Locations
- 🇺🇸
Cedars Sinai, Los Angeles, California, United States
🇺🇸Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States
🇺🇸University of California - San Francisco, San Francisco, California, United States
A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 345
- Registration Number
- NCT03972657
- Locations
- 🇺🇸
University of Virginia Health Systems - Emily Couric Clinical Cancer Center, Charlottesville, Virginia, United States
🇺🇸The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Providence Saint John's Health Center, Santa Monica, California, United States
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 412
- Registration Number
- NCT03969004
- Locations
- 🇫🇷
Centre Hospitalier Lyon Sud, Pierre Benite Cedex, France
🇪🇸Hospital Universitario Virgen Macarena-merge, Sevilla, Spain
🇫🇷Hospital Saint-Louis - APHP, Paris Cedex 10, France
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
- Conditions
- Interventions
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 73
- Registration Number
- NCT03916627
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-03-26
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 113
- Registration Number
- NCT03889912
- Locations
- 🇺🇸
NYU Langone, New York, New York, United States
🇺🇸Rochester Dermatologic Surgery, Victor, New York, United States
🇺🇸Duke Cancer Center, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.